← Eichor
Condition: Ground Glass Opacity Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Ground Glass Opacity

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Osimertinib to Suppress the Progression of GGN(EGFR Mutation-positive)
Phase 2 · 2 location(s) · Samsung Medical Center · NCT04591002Osimertinib to Suppress the Progression of Remaining GGN for EGFR Mutation-positive Stage IB-IIIA Lung Adenocarcinoma
Phase 2 · 1 location(s) · Samsung Medical Center · NCT05528458Cryoablation vs Thoracoscopic Surgery for GGN
NA · 1 location(s) · Shanghai Chest Hospital · NCT06848881Surveillance for Multifocal GGNs
Phase N/A · 1 location(s) · Fudan University · NCT06097910
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.